Losartan
Contraindicated throughout pregnancy. ARBs carry the same fetopathic mechanism as ACE inhibitors: inhibition of the renin-angiotensin system (RAS) disrupts fetal renal development. Second and third trimester exposure causes fetal renal tubular dysgenesis, oligohydramnios, skull hypoplasia, limb contractures, and fetal/neonatal death. First-trimester risk for cardiac defects has been reported. Discontinue immediately upon confirmed pregnancy.
